We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms (SCENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01716117
Recruitment Status : Completed
First Posted : October 29, 2012
Results First Posted : July 23, 2019
Last Update Posted : December 19, 2022
Information provided by (Responsible Party):
Stryker Neurovascular

Brief Summary:
This clinical research study is designed to determine safety and effectiveness of the Surpass Flow Diverter (Surpass System), an investigational device developed to treat wide-neck, large or giant intracranial aneurysms. An intracranial aneurysm is a bulge in the wall of a blood vessel in the brain. The bulge is caused by a weakening of the vessel wall. If left untreated, the bulge may continue to grow larger and ultimately the vessel may break open (rupture), resulting in serious bleeding into or around the brain. The information collected from this study will be used to evaluate how well patients do when treated with the Surpass System both immediately after treatment of an aneurysm and over a long period of time (5 years).

Condition or disease Intervention/treatment Phase
Brain Aneurysm Device: Surpass Flow Diverter Not Applicable

Detailed Description:
The objective of this study is to determine safety and effectiveness of the Surpass Flow Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked intracranial aneurysms in the internal carotid artery up to the terminus. The Surpass Flow Diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm. Use of the Surpass System may be associated with a decrease in neurological death or ipsilateral stroke in patients with large or giant wide-neck aneurysms. In a given patient, the Surpass System will be deemed effective if treatment results in complete occlusion of their aneurysm without clinically significant stenosis of the parent artery, or requires retreatment of the aneurysm through 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 213 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: The SCENT Trial is a multi-center, prospective, non-randomized trial.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT Trial)
Actual Study Start Date : October 25, 2012
Actual Primary Completion Date : December 11, 2016
Actual Study Completion Date : July 7, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Surpass Flow Diverter
The objective of this study is to determine the safety and effectiveness of the Surpass Flow Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked intracranial aneurysms in the internal carotid artery up to the terminus.
Device: Surpass Flow Diverter
Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm while allowing blood in the aneurysm to clot. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
Other Names:
  • Flow diverter
  • Endovascular aneurysm treatment

Primary Outcome Measures :
  1. mITT Primary Effectiveness Endpoint. Based on Subjects With 100% Occlusion of the Aneurysm Without Clinically Significant Stenosis of the Parent Artery, and Without Any Subsequent Treatment of the Target Aneurysm at the 12 Month Follow up Visit. [ Time Frame: 12 months ]
    Percent of subjects with 100% occlusion of the aneurysm without clinically significant stenosis (defined as less than or equal to 50% stenosis) of the parent artery based on core lab evaluation of the 12 month follow up angiogram and without any subsequent treatment of the target aneurysm at the 12 month follow up visit.

  2. mITT Primary Safety Endpoint. Based on Subjects Experiencing Neurologic Death or Major Ipsilateral Stroke Through 12 Month Follow-up. [ Time Frame: 12 months ]
    Subjects experiencing neurologic death or major ipsilateral stroke through 12 months.

Secondary Outcome Measures :
  1. Raymond-Roy Score Per Core Lab Assessment Based on Device Apposition at 12 Months Post-Procedure [ Time Frame: 12 months ]
    The Raymond-Roy intracranial aneurysm occlusion classification was used to assess the rate of aneurysm occlusion at the time of primary endpoint assessment (12 months). Occlusion rates were reported as Class I: complete obliteration (best); Class II: residual neck; Class III: residual aneurysm (worse).

Other Outcome Measures:
  1. Clinical Events Committee (CEC) Adjudicated Rate of Minor Strokes Through 12 Month Follow-Up [ Time Frame: 12 Months ]
    Patients with minor strokes through 12 months

  2. Subgroup Analysis of Primary Effectiveness Endpoint Based on Subject Age ≥ 65 Years Versus < 65 Years in mITT Population [ Time Frame: 12 Months ]
    Primary effectiveness by age group

  3. CEC Adjudicated Primary Effectiveness Endpoint Outcomes for Giant and Non-Giant (Large) Intracranial Aneurysms Through 12 Month Follow-Up - mITT Population [ Time Frame: 12 Months ]
    Primary effectiveness by intracranial aneurysm size

  4. Number of Surpass Streamline Flow Diverters Implanted Per Subject in SCENT Trial - mITT and Roll-In Populations [ Time Frame: 12 Months ]
    Number of devices implanted in subjects by study population

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 19 to 80 years
  • Subject or legal representative is willing and able to give informed consent
  • Subject has a single targeted intracranial aneurysm
  • Subject agrees to return to the treating Investigator for all scheduled follow up visits and is capable of returning to the hospital for follow up

Exclusion Criteria:

  • Known allergy or contraindication to aspirin, clopidogrel/Plavix, heparin, local or general anesthesia
  • Known history of life threatening allergy to contrast dye
  • Known allergy to nickel, chromium cobalt, tungsten or platinum
  • Subject has documented resistance to clopidogrel/Plavix
  • Major surgery within previous 30 days or planned in the next 120 days after enrollment date
  • Previous intracranial implant associated with the symptomatic distribution within the past 12 weeks prior to treatment date
  • Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to treatment date
  • Any previous stenting of parent artery at or proximal to the aneurysm where it would interfere with the placement and proper apposition of the device
  • Any previous coiling where it would interfere with the placement and proper apposition of the device
  • Platelet count less than 100,000 cells/mm3 or known platelet dysfunction
  • More than one intracranial aneurysm (IA) that requires treatment within 12 months
  • Asymptomatic extradural aneurysms requiring treatment
  • Contraindication to CT scan or MRI
  • Severe neurological deficit that renders the subject incapable of living independently
  • Unstable neurological deficit (i.e., worsening of clinical condition in the last 30 days)
  • Evidence of active infection at the time of treatment
  • Dementia or psychiatric problem that prevents the patient from completing required follow up
  • Co-morbid conditions that may limit survival to less than 24 months
  • Serum creatinine greater or equal to 2.5 mg/dL
  • Female subjects who are pregnant or planning to become pregnant within the study period
  • Subject with anatomy not appropriate for endovascular treatment due to severe intracranial vessel tortuosity or stenosis
  • Extra-cranial stenosis or parent vessel with stenosis greater than 50% in the area proximal to the aneurysm
  • Other known serious concurrent medical conditions
  • History of intracranial vasospasm not responsive to medical therapy
  • Subject with an intracranial mass, or is undergoing radiation therapy for carcinoma or sarcoma of the head or neck region
  • Subject has a history of bleeding diathesis or coagulopathy, international normalized ratio (INR) greater than 1.5, or will refuse blood transfusions
  • Subject had a subarachnoid hemorrhage within 30 days prior to the enrollment date
  • Subject has a non-treated arteriovenous malformation (AVM) in the territory of the target aneurysm
  • Inability to understand the study or a history of non-compliance with medical advice
  • Current use of illicit substance
  • Enrollment in another trial involving an investigational product
  • Subject has a need for long-term use of anticoagulants (i.e., Warfarin, Dabigatran)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01716117

Show Show 26 study locations
Sponsors and Collaborators
Stryker Neurovascular
Layout table for investigator information
Principal Investigator: Ricardo A Hanel, MD, PhD Lyerly Baptist Medical Center, Jacksonville, Florida
Principal Investigator: Philip M Meyers, MD Columbia University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Stryker Neurovascular
ClinicalTrials.gov Identifier: NCT01716117    
Other Study ID Numbers: SP-04
First Posted: October 29, 2012    Key Record Dates
Results First Posted: July 23, 2019
Last Update Posted: December 19, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to make IPD information available to other researchers. Blinded study data by mITT and Roll-in cohorts may be made available to SCENT researchers post publication of the primary study results.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Stryker Neurovascular:
Large aneurysm
Giant aneurysm
Wide neck aneurysm
Additional relevant MeSH terms:
Layout table for MeSH terms
Intracranial Aneurysm
Vascular Diseases
Cardiovascular Diseases
Intracranial Arterial Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Calcium Carbonate
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents